Jan M Keppel Hesselink

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2484208/publications.pdf

Version: 2024-02-01

471509 552781 47 783 17 26 citations g-index h-index papers 50 50 50 797 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	No Detectable Phenytoin Plasma Levels After Topical Phenytoin Cream Application in Chronic Pain: Inferences for Mechanisms of Action. Journal of Pain Research, 2022, Volume 15, 377-383.	2.0	2
2	Usefulness of a Double-Blind Placebo-Controlled Response Test to Demonstrate Rapid Onset Analgesia with Phenytoin 10% Cream in Polyneuropathy. Journal of Pain Research, 2020, Volume 13, 877-882.	2.0	8
3	Phenytoin Cream for the Treatment of Sciatic Pain: Clinical Effects and Theoretical Considerations: Case Report. Journal of Pain and Palliative Care Pharmacotherapy, 2020, 34, 99-105.	0.8	3
4	<p>Rediscovery of Ceruletide, a CCK Agonist, as an Analgesic Drug</p> . Journal of Pain Research, 2020, Volume 13, 123-130.	2.0	10
5	Ethical justification of single-blind and double-blind placebo-controlled response tests in neuropathic pain and N-of-1 treatment paradigm in clinical settings. Journal of Pain Research, 2019, Volume 12, 345-352.	2.0	5
6	<p>Topical loperamide for the treatment of localized neuropathic pain: a case report and literature review</p> . Journal of Pain Research, 2019, Volume 12, 1189-1192.	2.0	6
7	Phenytoin repositioned in wound healing: clinical experience spanning 60 years. Drug Discovery Today, 2018, 23, 402-408.	6.4	27
8	Single-Blind Placebo-Controlled Response Test with Phenytoin 10% Cream in Neuropathic Pain Patients. Pharmaceuticals, 2018, 11, 122.	3.8	11
9	Rediscovery of old drugs: the forgotten case of dermorphin for postoperative pain and palliation. Journal of Pain Research, 2018, Volume 11, 2991-2995.	2.0	16
10	"But that is your opinion": the dark side of postmodern pain medicine creating a postmodern patient autonomy. Journal of Pain Research, 2018, Volume 11, 2847-2851.	2.0	2
11	The retinoprotective role of phenytoin. Drug Design, Development and Therapy, 2018, Volume 12, 3485-3489.	4.3	9
12	Phenytoin Cream for the Treatment for Neuropathic Pain: Case Series. Pharmaceuticals, 2018, 11, 53.	3.8	17
13	On the importance of precision medicine for neuropathic pain. Pharmacy & Pharmacology International Journal, 2018, 6, .	0.2	О
14	Skin matters! The role of keratinocytes in nociception: a rational argument for the development of topical analgesics. Journal of Pain Research, 2017, Volume 10, 1-8.	2.0	34
15	Phenytoin: 80Âyears young, from epilepsy to breast cancer, a remarkable molecule with multiple modes of action. Journal of Neurology, 2017, 264, 1617-1621.	3.6	43
16	NS1209/SPD 502, A Novel Selective AMPA Antagonist for Stroke, Neuropathic Pain or Epilepsy? Drug Development Lessons Learned. Drug Development Research, 2017, 78, 75-80.	2.9	7
17	Phenytoin: a step by step insight into its multiple mechanisms of action—80Âyears of mechanistic studies in neuropharmacology. Journal of Neurology, 2017, 264, 2043-2047.	3.6	17
18	Phenytoin: neuroprotection or neurotoxicity?. Neurological Sciences, 2017, 38, 1137-1141.	1.9	17

#	Article	IF	CITATIONS
19	Fundamentals of and Critical Issues in Lipid Autacoid Medicine: A Review. Pain and Therapy, 2017, 6, 153-164.	3.2	5
20	Topical Phenytoin in Neuralgic Pain, Peripheral Modulation of Central Sensitization: Two Case Reports. Journal of Pain & Relief, 2017, 06, .	0.1	4
21	Palmitoylethanolamid and Other Lipid Autacoids Against Neuroinflammation, Pain, and Spasms in Multiple Sclerosis., 2017,, 29-37.		0
22	Topical phenytoin for the treatment of neuropathic pain. Journal of Pain Research, 2017, Volume 10, 469-473.	2.0	30
23	Bottlenecks in the development of topical analgesics: molecule, formulation, dose-finding, and phase III design. Journal of Pain Research, 2017, Volume 10, 635-641.	2.0	7
24	Resolvins and aliamides: lipid autacoids in ophthalmology & Drug Design, Development and Therapy, 2016, Volume 10, 3133-3141.	4.3	17
25	Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome. Journal of Pain Research, 2015, 8, 729.	2.0	28
26	Palmitoylethanolamide, a Natural Retinoprotectant: Its Putative Relevance for the Treatment of Glaucoma and Diabetic Retinopathy. Journal of Ophthalmology, 2015, 2015, 1-9.	1.3	19
27	Palmitoylethanolamide (PEA)—†Promiscuous' anti-inflammatory and analgesic molecule at the interface between nutrition and pharma. PharmaNutrition, 2014, 2, 19-25.	1.7	10
28	Vulvodynia and proctodynia treated with topical baclofen $5 \hat{A} \%$ and palmitoylethanolamide. Archives of Gynecology and Obstetrics, 2014, 290, 389-393.	1.7	26
29	Neuropathic Pain as a Result ofÂAcromegaly, Treated With Topical Baclofen Cream. Journal of Pain and Symptom Management, 2013, 46, e4-e5.	1.2	29
30	Treatment of chronic regional pain syndrome type 1 with palmitoylethanolamide and topical ketamine cream: modulation of nonneuronal cells. Journal of Pain Research, 2013, 6, 239.	2.0	21
31	Evolution in pharmacologic thinking around the natural analgesic palmitoylethanolamide: from nonspecific resistance to PPAR-α agonist and effective nutraceutical. Journal of Pain Research, 2013, 6, 625.	2.0	28
32	Central Neuropathic Pain in a Patient with Multiple Sclerosis Treated Successfully with Topical Amitriptyline. Case Reports in Medicine, 2012, 2012, 1-3.	0.7	21
33	Intractable neuropathic pain due to ulnar nerve entrapment treated with cannabis and ketamine 10%. Journal of Clinical Anesthesia, 2012, 24, 78-79.	1.6	4
34	Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. Journal of Pain Research, 2012, 5, 437.	2.0	69
35	High Doses of Topical Amitriptyline in Neuropathic Pain: Two Cases and Literature Review. Pain Practice, 2012, 12, 148-153.	1.9	59
36	New Targets in Pain, Non-Neuronal Cells, and the Role of Palmitoylethanolamide. Open Pain Journal, 2012, 5, 12-23.	0.4	50

#	Article	IF	CITATIONS
37	Enhancing Acupuncture by Low Dose Naltrexone. Acupuncture in Medicine, 2011, 29, 127-130.	1.0	8
38	Effectiveness of the association micronized N-palmitoylethanolamine (PEA)-transpolydatin in the treatment of chronic pelvic pain. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2011, 159, 488.	1.1	3
39	Topical Amitriptyline in Post-Traumatic Neuropathic Pain. Journal of Pain and Symptom Management, 2011, 41, e6-e7.	1.2	23
40	Multimodal Stepped Care Approach Involving Topical Analgesics for Severe Intractable Neuropathic Pain in CRPS Type 1: A Case Report. Case Reports in Medicine, 2011, 2011, 1-4.	0.7	17
41	A New Combination Cream forÂtheÂTreatment of Severe Neuropathic Pain. Journal of Pain and Symptom Management, 2010, 39, e9-e10.	1.2	12
42	Nerve Regeneration in Neuropathic Pain. Pain Medicine, 2010, 11, 1576-1576.	1.9	2
43	Letter to the Editor. Current Therapeutic Research, 2010, 71, 416-417.	1.2	O
44	Evolution of concepts and definitions of Parkinson's disease since 1817*. Journal of the History of the Neurosciences, 1996, 5, 200-207.	0.9	6
45	Ipsapirone in the treatment of bulimia nervosa: An open pilot study. International Journal of Eating Disorders, 1995, 17, 359-363.	4.0	15
46	Behavioral pharmacology of serotonin receptor subtypes: hypotheses for clinical applications of selective serotonin ligands. International Review of Psychiatry, 1995, 7, 41-53.	2.8	7
47	A phase II multicenter dose-finding, efficacy and safety trial of ipsapirone in outpatients with generalized anxiety disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1994, 18, 447-463.	4.8	27